Opioid-Independent Surgical Anesthetic via Biphasic Lipid Matrix
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current postoperative pain management regimens rely heavily on opioids, leading to addiction and overdose risks, and existing long-acting local anesthetics are ineffective, costly, and cumbersome to administer, failing to provide sustained analgesia at surgical sites.
Innovation Solution
Development of an opioid-independent surgical anesthetic composition comprising a hydrogel with solid lipid matrix particles entrapping lipophilic local anesthetics like bupivacaine, which releases the anesthetic in a biphasic manner, offering a burst phase followed by sustained release, reducing the need for systemic opioids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional local anesthetics are administered to treat postoperative pain, then analgesia is provided at the surgical site, but the duration of analgesia is limited to only a few hours
Solution Approach 1:
The anesthetic is segmented into two distinct phases: a burst phase that provides immediate high-concentration analgesia, and a sustained release phase that maintains therapeutic levels over extended periods. This segmentation resolves the contradiction by delivering both immediate relief and long-lasting effect without requiring frequent re-administration
Solution Approach 2:
The formulation is prepared in advance with a high concentration of anesthetic embedded in the lipid matrix, creating a reservoir that automatically releases the drug over time. This preliminary action eliminates the need for repeated injections while ensuring adequate pain control from the outset
2Duration of action of moving object
If iterative doses of local anesthetic are administered to extend analgesia duration, then pain management is improved, but the procedure becomes time-consuming and introduces infection risk
Solution Approach 1:
The lipid matrix formulation provides continuous anesthetic release from a single administration, maintaining therapeutic concentrations throughout the desired period. This continuous action eliminates the need for multiple discrete injection procedures, reducing both time commitment and infection risk while sustaining pain relief
3Duration of action of moving object
If existing long-acting local anesthetic products are used, then extended analgesia is purported to be provided, but they suffer from high cost and complicated drug delivery procedures
Solution Approach 1:
The invention changes the physical-chemical parameters of the anesthetic formulation by embedding it in a lipid matrix with specific melting properties. This parameter change enables controlled release kinetics and extended duration of action using simple injection equipment, avoiding the need for complex delivery systems while achieving long-lasting analgesia
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition provides effective, long-lasting analgesia at surgical sites, reducing opioid dependency and overdose risks by offering a single, easy-to-administer product that manages both acute and lingering postoperative pain without the complexities of existing methods.
Implementation Method 1
the plurality of solid lipid matrix particles includes a lipophilic local anesthetic drug and releases the anesthetic in a biphasic manner
Implementation Method 2
releases the anesthetic in a biphasic manner, offering a burst phase followed by sustained release
Implementation Method 3
an injectable dosage form of a hydrogel that has a plurality of solid lipid matrix particles entrapped therein
Data Source
Figure 1A
Figure 1B
Figure 2A~2B
AI summary
An opioid independent surgical anesthetic composition includes an injectable dosage form of a hydrogel having a plurality of solid lipid matrix particles entrapped therein. The solid lipid matrix particles include a lipophilic local anesthetic drug and a lipid glyceride (e.g., saturated triglyceride or lipid blend of various lipid glycerides). Methods for creating a long-acting local anesthetic product can include creating a bulk solid of a lipid matrix product by heating a lipid solvent above its melting point, dissolving a lipophilic local anesthetic drug therein, reducing a temperature of the resultant drug-lipid solution to below the melting point of the lipid solvent, and heat annealing the lipid matrix to remove or reduce presence of any unstable polymorphs in the lipid matrix. The methods can further include crushing the bulk solid of the lipid matrix product to form solid lipid matrix particles and entrapping the solid lipid matrix particles within a hydrogel.